Format

Send to

Choose Destination
BMC Res Notes. 2015 Mar 26;8:99. doi: 10.1186/s13104-015-1055-6.

Noninvasive diagnosis of chemotherapy induced liver injury by LiMAx test--two case reports and a review of the literature.

Author information

1
Department of General, Visceral and Transplantation Surgery, Charité University Hospital, Augustenburger Platz 1, 13353, Berlin, Germany. jan.bednarsch@charite.de.
2
Department of General, Visceral and Transplantation Surgery, Charité University Hospital, Augustenburger Platz 1, 13353, Berlin, Germany. maximilian.jara@med.uni-muenchen.de.
3
Department of General, Visceral and Transplantation Surgery, Charité University Hospital, Augustenburger Platz 1, 13353, Berlin, Germany. lock_j@ukw.de.
4
Department of General, Visceral and Transplantation Surgery, Charité University Hospital, Augustenburger Platz 1, 13353, Berlin, Germany. maciej.malinowski@charite.de.
5
Department of General, Visceral and Transplantation Surgery, Charité University Hospital, Augustenburger Platz 1, 13353, Berlin, Germany. johann.pratschke@charite.de.
6
Department of General, Visceral and Transplantation Surgery, Charité University Hospital, Augustenburger Platz 1, 13353, Berlin, Germany. martin.stockmann@charite.de.

Abstract

BACKGROUND:

Chemotherapy-induced liver injury is a well-known phenomenon after neoadjuvant therapy of liver metastasis and contributes to postoperative morbidity and mortality. Still there is no suitable test available to reliably determine functional impairment and hepatic regeneration after chemotherapy.

CASE PRESENTATION:

We report two cases of caucasian patients who underwent repeated liver function assessments using LiMAx (maximum liver function capacity), Indocyanine plasma disappearance rate and biochemical liver function parameters in the course of adjuvant oxaliplatin-based chemotherapy. Both patients yielded a decrease from their initial liver function determined by LiMAx. Liver regeneration assessed functional recovery within 4 weeks in case of mild functional impairment after cessation of chemotherapy or within 8 weeks in case of major functional deterioration. Indocyanine plasma disappearance rate and biochemical parameters remained stable or without a clear trend in case of minor functional impairment. This is the first report using a dynamic liver function test to evaluate the impact and recovery from chemotherapy associated liver injury.

CONCLUSIONS:

The LiMAx test might be a sensitive tool to diagnose mild functional impairment after chemotherapy when standard liver function tests have remained within normal ranges and might be capable to assess the course of regeneration after chemotherapy. This could be useful to optimize individual chemotherapy-free interval before liver surgery can be carried out safely.

PMID:
25889706
PMCID:
PMC4403679
DOI:
10.1186/s13104-015-1055-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center